Novel platinum compounds have been sought with the goal of identifying molecules active
in cisplatin-resistant cancers such as colorectal cancer. Some 30 years ago it was shown …

Oxaliplatin (Eloxatin; Sanofi, Gentilly, France), a third-generation platinum compound with a
1, 2-diaminocyclohexane (DACH) carrier ligand, is a recently developed agent with activity …

Oxaliplatin is a novel platinum analogue which has wide spectrum anti‐cancer activity in in
vitro systems. It has distinct biochemical, pharmacological and cytotoxic properties which are …

For nearly 40 years, the medical treatment of colorectal cancer had been limited to the
fluoropyrimidines until the recent development of irinotecan (CPT-11). In the past decade, a …

Oxaliplatin (Eloxatin) has demonstrated significant activity in a variety of tumor types in
addition to colorectal cancer. Several studies have reported on the effectiveness of …

Oxaliplatin is the only third-generation platinum derivative compound that has found a place
in the routine treatment of colorectal cancer (CRC). The appearance of oxaliplatin, as well as …

Introduction: Oxaliplatin, a second-generation platinum analog, has evolved as one of the
most important therapeutic agents in colorectal cancer (CRC) treatment. It has had a major …

One of the more promising chemotherapeutic agents for patients with metastatic colorectal
cancer is oxaliplatin (Eloxatin), a third-generation platinum derivative with a unique …

Significant advances in the treatment of colorectal cancer have been observed over the past
several years. With the introduction of oxaliplatin combined with infusional 5-fluorouracil and …

OXALIPLATIN IS a third-generation platinum compound with a 1, 2 diaminocyclohexane
carrier ligand. This important difference in the molecule, and hence in the DNA adducts …